X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (27) 27
humans (26) 26
cancer (25) 25
immunology (23) 23
oncology (23) 23
dendritic cells (18) 18
immunotherapy (15) 15
female (13) 13
life sciences (13) 13
nk cells (13) 13
animals (12) 12
natural-killer-cells (11) 11
expression (10) 10
mice (10) 10
t cells (10) 10
adult (9) 9
cell biology (9) 9
male (9) 9
peptides (9) 9
t-lymphocytes - immunology (9) 9
tumors (9) 9
lymphocytes (8) 8
middle aged (8) 8
original research (7) 7
aged (6) 6
immunity (6) 6
melanoma (6) 6
metastatic melanoma (6) 6
mice, inbred c57bl (6) 6
t-cells (6) 6
antigens (5) 5
antitumor immunity (5) 5
cell line, tumor (5) 5
chemotherapy (5) 5
health aspects (5) 5
ipilimumab (5) 5
medicine, research & experimental (5) 5
melanoma - immunology (5) 5
melanoma - pathology (5) 5
neoplasms - immunology (5) 5
prognosis (5) 5
care and treatment (4) 4
chronic myelogenous leukemia (4) 4
chronic myeloid-leukemia (4) 4
cohort studies (4) 4
dendritic cells - immunology (4) 4
flow cytometry (4) 4
gastrointestinal stromal tumors (4) 4
human health and pathology (4) 4
imatinib mesylate (4) 4
immunotherapy - methods (4) 4
innate immunity (4) 4
leukemia, myelogenous, chronic, bcr-abl positive - immunology (4) 4
medical and health sciences (4) 4
medicin och hälsovetenskap (4) 4
melanoma - therapy (4) 4
neoplasms (4) 4
neoplasms - drug therapy (4) 4
nkp30 (4) 4
[ sdv.imm ] life sciences [q-bio]/immunology (3) 3
[sdv.imm]life sciences [q-bio]/immunology (3) 3
aged, 80 and over (3) 3
antibodies, monoclonal - therapeutic use (3) 3
antigen presentation (3) 3
antineoplastic agents - therapeutic use (3) 3
apoptosis (3) 3
article (3) 3
c-kit (3) 3
calreticulin exposure (3) 3
cells (3) 3
chemical and pharmacologic phenomena (3) 3
combined modality therapy (3) 3
cytotoxicity (3) 3
cytotoxicity receptors (3) 3
efficacy (3) 3
fusion proteins, bcr-abl - metabolism (3) 3
histocompatibility antigens (3) 3
hla histocompatibility antigens (3) 3
il-2 (3) 3
immune checkpoint (3) 3
immune-response (3) 3
immunohistochemistry (3) 3
immunosurveillance (3) 3
interferon-gamma (3) 3
killer cells, natural - immunology (3) 3
killer cells, natural - metabolism (3) 3
leukemia (3) 3
lymphocytes, tumor-infiltrating - immunology (3) 3
medical research (3) 3
melanoma - mortality (3) 3
multidisciplinary sciences (3) 3
neoplasms - pathology (3) 3
nsclc (3) 3
peptide fragments - immunology (3) 3
receptors (3) 3
regulatory t cells (3) 3
regulatory t-cells (3) 3
research (3) 3
t-lymphocytes - drug effects (3) 3
t-lymphocytes - metabolism (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Medicine, ISSN 1078-8956, 2011, Volume 17, Issue 6, pp. 700 - 707
The natural killer (NK) cell receptor NKp30 is involved in the recognition of tumor and dendritic cells (DCs). Here we describe the influence of three NKp30... 
MEDICINE, RESEARCH & EXPERIMENTAL | NATURAL-KILLER-CELLS | HUMAN DENDRITIC CELLS | BIOCHEMISTRY & MOLECULAR BIOLOGY | IL-10 PRODUCTION | C-KIT | TRIGGERING RECEPTOR | CELL BIOLOGY | NK CELLS | CLASS-III | CYTOTOXICITY RECEPTORS | HUMAN MHC | EXPRESSION | Prognosis | Alternative Splicing - genetics | Humans | Interleukin-12 - physiology | Lysosomal-Associated Membrane Protein 1 - physiology | Interferon-gamma - physiology | Alternative Splicing - physiology | Gastrointestinal Stromal Tumors - physiopathology | Natural Cytotoxicity Triggering Receptor 3 - genetics | Natural Cytotoxicity Triggering Receptor 3 - physiology | Killer Cells, Natural - physiology | Proto-Oncogene Proteins c-kit - physiology | Gastrointestinal Stromal Tumors - diagnosis | Protein Isoforms | Tumor Necrosis Factor-alpha - physiology | Cell Line, Tumor | Polymorphism, Single Nucleotide - genetics | Proto-Oncogene Proteins c-kit - genetics | Gastrointestinal Stromal Tumors - genetics | Dendritic cells | Gastrointestinal tumors | Physiological aspects | Genetic aspects | Research | Gene expression | Interferon | Medical prognosis | Gastrointestinal diseases | Tumors | Cancer | Interferon-gamma | Killer Cells, Natural | Alternative Splicing | Natural Cytotoxicity Triggering Receptor 3 | Interleukin-12 | Proto-Oncogene Proteins c-kit | Tumor Necrosis Factor-alpha | Life Sciences | Lysosomal-Associated Membrane Protein 1 | Immunology | Polymorphism, Single Nucleotide | Gastrointestinal Stromal Tumors
Journal Article
Science, ISSN 0036-8075, 11/2015, Volume 350, Issue 6264, pp. 1079 - 1084
Journal Article
细胞研究:英文版, ISSN 1001-0602, 2015, Volume 25, Issue 2, pp. 208 - 224
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 07/2016, Volume 13, Issue 7, pp. 431 - 446
Around 15 years ago, imatinib mesylate (Gleevec (R) or Glivec (R), Novartis, Switzerland) became the very first 'targeted' anticancer drug to be clinically... 
CHRONIC MYELOGENOUS LEUKEMIA | CYTOTOXIC T-CELLS | KILLER DENDRITIC CELLS | ONCOLOGY | COMPLETE MOLECULAR REMISSION | MINOR HISTOCOMPATIBILITY ANTIGENS | ACUTE LYMPHOBLASTIC-LEUKEMIA | TYROSINE KINASE INHIBITOR | PATIENTS RECEIVING IMATINIB | GASTROINTESTINAL STROMAL TUMORS | CHRONIC MYELOID-LEUKEMIA | Tumor Escape - drug effects | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Agents - therapeutic use | B7 Antigens - immunology | Drug Approval | Protein-Tyrosine Kinases - immunology | Hematopoiesis - drug effects | Natural Cytotoxicity Triggering Receptor 3 - drug effects | Imatinib Mesylate - therapeutic use | Immunity, Cellular - drug effects | Immune Tolerance - immunology | T-Lymphocytes - drug effects | Protein-Tyrosine Kinases - drug effects | Killer Cells, Natural - immunology | Molecular Chaperones - drug effects | Natural Cytotoxicity Triggering Receptor 3 - immunology | Vascular Endothelial Growth Factor A - drug effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - immunology | Molecular Chaperones - immunology | Molecular Targeted Therapy - methods | Gastrointestinal Stromal Tumors - immunology | Immune Tolerance - drug effects | Tumor Escape - immunology | Antigens, Neoplasm - immunology | Antineoplastic Agents - immunology | B7 Antigens - drug effects | Vascular Endothelial Growth Factor A - immunology | Immunologic Surveillance - drug effects | Forecasting | Immunologic Surveillance - immunology | Hematopoiesis - immunology | Imatinib Mesylate - immunology | Gastrointestinal Stromal Tumors - drug therapy | T-Lymphocytes - immunology | Killer Cells, Natural - drug effects | Antigens, Neoplasm - drug effects | Tyrosine | Care and treatment | Analysis | Immunotherapy | B cells | Drug approval | Cancer
Journal Article
Immunity, ISSN 1074-7613, 10/2016, Volume 45, Issue 4, pp. 931 - 943
Journal Article
CANCER RESEARCH, ISSN 0008-5472, 06/2013, Volume 73, Issue 12, pp. 3499 - 3510
Cancer immunosurveillance relies on effector/memory tumor-infiltrating CD8(+) T cells with a T-helper cell 1 (T(H)1) profile. Evidence for a natural killer... 
NATURAL-KILLER-CELLS | INHIBITION | EFFICACY | ONCOLOGY | C-KIT | MUTATIONS | CYTOTOXIC ACTIVITY | CANCER | EXPRESSION | IMATINIB MESYLATE | PREDICTION | Forkhead Transcription Factors - immunology | Immunohistochemistry | Multivariate Analysis | Pyrimidines - immunology | Prognosis | Humans | Middle Aged | Male | Benzamides - therapeutic use | Flow Cytometry | T-Lymphocytes - metabolism | Forkhead Transcription Factors - metabolism | Protein Kinase Inhibitors - immunology | T-Lymphocytes - drug effects | Aged, 80 and over | Killer Cells, Natural - immunology | Adult | Female | Lymphocytes, Tumor-Infiltrating - metabolism | CD56 Antigen - immunology | Natural Cytotoxicity Triggering Receptor 1 - immunology | Gastrointestinal Stromal Tumors - immunology | CD56 Antigen - metabolism | Kaplan-Meier Estimate | Treatment Outcome | Piperazines - therapeutic use | Lymphocytes, Tumor-Infiltrating - drug effects | Benzamides - immunology | CD3 Complex - metabolism | Imatinib Mesylate | Gastrointestinal Stromal Tumors - drug therapy | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | CD3 Complex - immunology | Piperazines - immunology | Gastrointestinal Stromal Tumors - metabolism | Natural Cytotoxicity Triggering Receptor 1 - metabolism | T-Lymphocytes - immunology | Aged | Killer Cells, Natural - drug effects | Killer Cells, Natural - metabolism | Cohort Studies | Lymphocytes, Tumor-Infiltrating - immunology
Journal Article
Cell Research, ISSN 1001-0602, 02/2015, Volume 25, Issue 2, pp. 208 - 224
The cytotoxic T lymphocyte antigen-4 (CTLA-4)-blocking antibody ipilimumab induces immune-mediated long-term control of metastatic melanoma in a fraction of... 
sCD25 | tumor immunotherapy | ipilimumab | IL-2 | cancer | CTLA-4 blockade | Original | CD122
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 03/2016, Volume 126, Issue 3, pp. 921 - 937
Journal Article